Effects of nitroprusside and nitroglycerin on cGMP content and PGI2 formation in aorta and vena cava.
Nitroprusside (NP) and nitroglycerin (NG) are potent vasodilators that are used clinically on the basis of their abilities to cause relaxation of smooth muscle. In vitro, both agents cause activation of guanylate cyclase, resulting in increased intracellular cGMP. They also have effects on arachidonate metabolism. Despite apparent similarities in their mechanisms of action, the two drugs have different therapeutic applications based in part on differences in their effectiveness on the arterial and venous systems in vivo. To understand better their target tissue preference, slices of aorta and vena cava were incubated with the agents; cGMP and the vasodilatory prostanoid, prostacyclin, were quantified. NP was more effective in increasing the cGMP content of aorta than of vena cava; it was more active than NG in both tissues. Prostaglandin formation by vascular tissue was influenced by the preliminary equilibration period. Under optimal conditions, it appeared that NG enhanced prostacyclin formation in aorta more than did NP. This in vitro model for NP and NG action may be useful in studying the mechanisms of action of these and other vasoactive agents.
Tsai
S C
SC
Laboratory of Cellular Metabolism, National Heart, Lung, and Blood Institute, Bethesda, MD 20892.
Adamik
R
R
Manganiello
V C
VC
Moss
J
J
D000818:Animals; D001011:Aorta / Q000187:drug effects* / Q000378:metabolism; D006152:Cyclic GMP / Q000032:analysis*; D011464:Epoprostenol / Q000096:biosynthesis*; D005292:Ferricyanides / Q000494:pharmacology*; D008297:Male; D005996:Nitroglycerin / Q000494:pharmacology*; D009599:Nitroprusside / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D014684:Venae Cavae / Q000187:drug effects* / Q000378:metabolism
D005292:Ferricyanides; D009599:Nitroprusside; D011464:Epoprostenol; D005996:Nitroglycerin; D006152:Cyclic GMP